Christopher Long, MD
Ophthalmology · Pasadena, CANPI 1023634516
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,423 of the $6,064 with a category attached, or 72.9%. 15 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 37.9% of the total. Reporting peaked in 2023 at $2,928 and has fallen 51.2% since, to $1,428 in 2025.
Across 90 payments — averaging $67.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$2K
- Alcon$2K
- AbbVie$400
- Tarsus Pharmaceuticals, Inc.$348
- Carl Zeiss Meditec USA, Inc.$189
- Johnson & Johnson Surgical Vision, Inc.$132
- plus $400 from 9 others
What the payments were for
- Travel & lodging$1,64127%
- Food & beverage$4,42373%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 20 | $2,298 |
| Alcon | 26 | $2,296 |
| AbbVie | 13 | $400 |
| Tarsus Pharmaceuticals, Inc. | 8 | $348 |
| Carl Zeiss Meditec USA, Inc. | 3 | $189 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $132 |
| Sun Pharmaceutical Industries Inc. | 4 | $96 |
| Thea Pharma Inc. | 3 | $68 |
| Harrow Eye, LLC | 2 | $50 |
| Amgen | 2 | $46 |
| Sight Sciences, Inc. | 2 | $40 |
| Oyster Point Pharma, Inc. | 1 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Dompe US, Inc. | 1 | $25 |
| Rxsight Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS ELITE$1,644
- enVista MX60 IOL$1,644
- Trulign IOL$1,644
- Crystalens Accommodating IOL (AT-52AO)$1,644
- Hydrus Microstent$759
- Clareon$403
- QUATERA 700$153
- IOLMaster 700$153
- Centurion$149
- MIEBO$133
- VYZULTA$133
- Clareon PanOptix Pro$132
- Rocklatan$125
- Rhopressa$125
- STELLARIS$120
- XDEMVY$120
How this compares
$6,064 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 89 | $2,693 |
| Brimonidine Tartrate | 19 | $2,112 |
| Ketorolac Tromethamine | 55 | $1,389 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 63 | $1,169 |
| Ofloxacin | 64 | $771 |
| Latanoprost | 121 | $674 |
| MoxifloxacinMoxifloxacin Hcl | 14 | $242 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Pasadena
- Srinivas SaddaPasadena$1M
- Michael IpPasadena$181K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.